Information Provided By: 
Fly News Breaks for December 15, 2015
NVAX
Dec 15, 2015 | 06:53 EDT
Piper Jaffray analyst Edward Tenthoff says Novavax's completed enrollment for the Phase III RESOLVE trial of its RSV-F vaccine positions the company to report top-line data in the second half of 2016. The analyst is confident the study will meet the primary endpoint of reduction in moderate-to-severe RSV-caused lower respiratory tract infection. He recommends owning the stock into the data and calls Novavax a top pick for 2016. Tenthoff reiterates an Overweight rating on the name with a $15 price target.
News For NVAX From the Last 2 Days
There are no results for your query NVAX
